{"doc_id": "si-2024-0003-reg-1", "parent_doc_id": "si-2024-0003", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 3 of 2024", "title": "2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the", "year": 2024, "heading": "1. (1) These Regulations may be cited as the European Union (Clinical", "text_raw": "1. (1) These Regulations may be cited as the European Union (Clinical \nTrials on Medicinal Products for Human Use) (Amendment) Regulations 2024. \n\n(2) The Principal Regulations, the European Union (Clinical Trials on \nMedicinal Products for Human Use) (Principal) (Amendment) Regulations \n2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the \nEuropean Union (Clinical Trials on Medicinal Products for Human Use) \nRegulations 2022 to 2024.", "text_norm": "1 (1) regulation may cited european union (clinical trial medicinal product human use) (amendment) regulation 2024 (2) principal regulation european union (clinical trial medicinal product human use) (principal) (amendment) regulation 2022 (s.i no 418 2022) regulation may cited together european union (clinical trial medicinal product human use) regulation 2022 2024", "start_char": 630, "end_char": 1097, "source_path": "downloads\\2024\\2024_0003.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d77bbc3394a8247790370f3ac8ce6c1d73a959179faf580644a3c2d0d3326db", "cross_refs": []}
{"doc_id": "si-2024-0003-reg-2", "parent_doc_id": "si-2024-0003", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 3 of 2024", "title": "2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the", "year": 2024, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the European Union (Clinical Trials on \nMedicinal Products for Human Use) (Principal) Regulations 2022 (S.I. No. 99 \nof 2022); \n\n“Regulations of 2022” means the European Union (Clinical Trials on \nMedicinal Products for Human Use) (Principal) (Amendment) Regulations \n2022 (S.I. No. 727 of 2022).", "text_norm": "2 regulations-- principal regulation mean european union (clinical trial medicinal product human use) (principal) regulation 2022 (s.i no 99 2022) regulation 2022 mean european union (clinical trial medicinal product human use) (principal) (amendment) regulation 2022 (s.i no 727 2022)", "start_char": 1097, "end_char": 1455, "source_path": "downloads\\2024\\2024_0003.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d77bbc3394a8247790370f3ac8ce6c1d73a959179faf580644a3c2d0d3326db", "cross_refs": []}
{"doc_id": "si-2024-0003-reg-3", "parent_doc_id": "si-2024-0003", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 3 of 2024", "title": "2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the", "year": 2024, "heading": "3. The Principal Regulations are amended by substituting for Regulation", "text_raw": "3. The Principal Regulations are amended by substituting for Regulation \n\n61A (inserted by Regulation 2 of the Regulations of 2022) the following: \n\n“61A. A notice of amendment under Regulation 21(3) of the European \nCommunities (Clinical Trials on Medicinal Products for Human Use) \nRegulations 2004 to which Regulation 61(a) applies shall be made to the \nNational Office and, in the case of commercial trials, a fee of €400 shall \napply in connection with each such notification.”.", "text_norm": "3 principal regulation amended substituting regulation 61a (inserted regulation 2 regulation 2022) following 61a notice amendment regulation 21(3) european community (clinical trial medicinal product human use) regulation 2004 regulation 61(a) applies shall made national office case commercial trial fee eur400 shall apply connection notification", "start_char": 1455, "end_char": 1941, "source_path": "downloads\\2024\\2024_0003.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d77bbc3394a8247790370f3ac8ce6c1d73a959179faf580644a3c2d0d3326db", "cross_refs": []}
{"doc_id": "si-2024-0003-reg-4", "parent_doc_id": "si-2024-0003", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 3 of 2024", "title": "2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the", "year": 2024, "heading": "4. The Regulations of 2022 are revoked.", "text_raw": "4. The Regulations of 2022 are revoked. \n\nGIVEN under my Official Seal, \n\n8 January, 2024. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n1 OJ No. L 158, 27.5.2014, p. 1. \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 12th January, 2024. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[3] 3", "text_norm": "4 regulation 2022 revoked given official seal 8 january 2024 stephen donnelly minister health 1 oj no l 158 27.5.2014 p 1 notice making statutory instrument published iris oifigiuil 12th january 2024 3 3", "start_char": 1941, "end_char": 2254, "source_path": "downloads\\2024\\2024_0003.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d77bbc3394a8247790370f3ac8ce6c1d73a959179faf580644a3c2d0d3326db", "cross_refs": []}
{"doc_id": "si-2024-0003-explanatory-note", "parent_doc_id": "si-2024-0003", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 3 of 2024", "title": "2022 (S.I. No. 418 of 2022) and these Regulations may be cited together as the", "year": 2024, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the European Union (Clinical Trials on Medicinal \nProducts for Human Use) (Principal) Regulations 2022 to update the fees \npayable to the National Office in respect of applications coming under the \nremaining transitional provisions that apply in respect of the repeal of the \nEuropean Communities (Clinical Trials on Medicinal Products for Human Use) \nRegulations 2004. \n\n \n \n \n \n \n\f4 [3] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-516) 30. 1/24. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend european union (clinical trial medicinal product human use) (principal) regulation 2022 update fee payable national office respect application coming remaining transitional provision apply respect repeal european community (clinical trial medicinal product human use) regulation 2004 4 3 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-516) 30 1 24 propylon", "start_char": 2254, "end_char": 3268, "source_path": "downloads\\2024\\2024_0003.pdf", "extraction_method": "pdfminer", "checksum": "sha256:2d77bbc3394a8247790370f3ac8ce6c1d73a959179faf580644a3c2d0d3326db", "cross_refs": []}
